A "normal" BMI is supposed to be the all-clear. For Indian bodies, it often is not. A significant proportion of Asian Indians carry high body fat and high visceral fat, and show insulin resistance that would prompt clinical concern, while their BMI still reads as healthy. The reason is that a single BMI cut-off cannot capture how Indians store fat. At the same number on the scale, Indian bodies tend to carry more fat and more of it around the organs. If you have done everything right and your weight looks fine but your energy, labs or waistline say otherwise, the BMI category may not be the signal to trust.
India has recently updated its obesity definition, lowering the threshold to a BMI of 23 for Asian Indian adults.

• The standard BMI thresholds were built on European population data and consistently underestimate fat and metabolic risk in Indian bodies.
• At the same "normal" BMI, studies find Asian Indians show roughly 37 to 40% lower insulin sensitivity than Europeans.
• Research in non-obese Indian adults suggests a large proportion may already meet an insulin-resistance threshold despite a normal weight reading.
• The most useful home check is waist-to-height ratio (under 0.5) and waist circumference (under 90 cm for men, under 80 cm for women).
• Consumer smart scales give unreliable visceral-fat readings in Indian bodies: use waist tape, not the device's internal estimate.

BMI is a ratio of weight to height. It says nothing about where fat sits, how much of your body is fat versus muscle, or what that fat is doing to your liver and pancreas. Two people at the same "normal" BMI can have very different amounts of visceral fat, the deep abdominal fat wrapped around the organs.

Standard BMI thresholds were derived largely from white European populations, then applied worldwide as if bodies were interchangeable. They are not. At the same BMI, Asian Indians tend to have more total and visceral fat and less muscle than Europeans, which is why Indian medical bodies have long used lower cut-offs.

For nearly two decades, the Indian standard placed overweight at 23 kg/m² and obesity at 25 kg/m², rather than the Western thresholds of 25 and 30. India's 2025 expert consensus has since moved the obesity threshold further, to 23 kg/m², reflecting what research consistently finds about metabolic risk at lower body weights in this population.

So a BMI of 24, comfortably "normal" on a Western chart, now sits squarely in the obesity range for an Indian adult under the latest clinical guidance. The belief that a normal BMI means metabolic safety is not wrong because the maths is faulty. It is wrong because the reference body the maths was built on was never the Indian body.

When researchers measure insulin sensitivity directly rather than trusting BMI, non-obese Indians look very different from their weight category. Insulin resistance, not the scale, is the earliest quiet marker of metabolic trouble.

In a clamp study of healthy men matched for age and BMI, Asian Indians had roughly 37% lower glucose disposal than Caucasians (4.7 versus 7.5 mg per kg per minute) despite similar total body fat, with more CT-measured visceral fat. A later study of South Asians and Caucasians, both at a mean BMI of around 25, found insulin sensitivity about 40% lower in the South Asians, with fasting insulin roughly double. The pattern holds across different research settings, not just studies conducted within India.

Raji, JCEM (2001)

Participants: 12 Indian men and 12 Caucasian men matched for BMI.

Key finding: Indian participants showed about 37% lower glucose disposal and had more visceral fat, despite having a similar BMI.

Trikudanathan, Metabolism (2013)

Participants: 23 South Asian adults and 18 Caucasian adults with an average BMI of around 25.

Key finding: Insulin sensitivity about 40% lower, fasting insulin about double

TyG Index Study, Diabetes (2020)

Participants: 170 non-obese adults with a mean BMI of 22.1.

Key finding: 44% were insulin resistant based on the triglyceride-glucose (TyG) index despite having a non-obese BMI.

Lean NAFLD Series, Trop Gastro (2013)

Participants: 23 lean patients with fatty liver (BMI below 23).

Key finding: 80% were insulin resistant, even though they had a normal weight and waist measurement.

Taken together, once insulin sensitivity is measured directly rather than inferred from weight, a substantial proportion of "non-obese" Asian Indians in these cohorts already meet an insulin-resistance threshold. BMI substantially underestimates metabolic risk in this group. It is not that these people are hiding obesity. It is that the risk lives in a place BMI cannot see.

The consequence of trusting BMI alone is a missed window. There is a recognised clinical pattern called "metabolically obese, normal weight," where BMI is under 25 but waist circumference, triglycerides, fasting glucose and liver markers all point toward risk. These are the people who get reassured by a normal weight and screened too late.

The stakes are concrete. A meaningful share of type 2 diabetes in India appears in people below the conventional obesity threshold. Lean fatty liver is more common in Indian adults than is often appreciated, and hidden visceral fat can sit behind a perfectly normal weight reading. Young-onset diabetes at normal BMI is substantially more common in Asian Indians than in white Europeans in multi-ethnic data, and the gap is large enough to carry practical clinical implications.

The picture is not uniform across everyone, and honest science says so. Young Indian women in some studies do not show the same pattern of excess visceral fat or insulin resistance as men of similar BMI, suggesting the phenotype is modulated by sex and life stage. Where it does appear clearly in women is alongside PCOS and after menopause.

Research in Indian women with PCOS finds that a meaningful proportion of those who are non-obese by BMI are already insulin-resistant, carrying more visceral fat than weight-matched peers without the condition. In postmenopausal women, normal BMI may coexist with clustering cardiometabolic risk driven by visceral fat accumulation that the scale does not detect. For many Indian women, PCOS, thyroid status and menopause shift the risk well before the scale does.

Waist-to-height ratio

• Target: Keep it below 0.5, meaning your waist should measure less than half your height.
• Why it matters: A higher ratio is associated with an increased risk of diabetes and heart disease, even when BMI falls within the normal range.

Waist circumference

• Target: Keep it under 90 cm for men and under 80 cm for women.
• Why it matters: Exceeding these measurements is linked with a substantially higher risk of metabolic syndrome

The best single predictor of cardiometabolic risk was a waist-to-height ratio of around 0.51 to 0.55, and Indian cut off put raised waist at 90 cm for men and 80 cm for women. These are lower than Western thresholds, reflecting the higher risk at a given waist size in Indian bodies.

Beyond the tape measure, fasting blood tests add a great deal. Simple indices that combine fasting triglycerides and glucose, such as the triglyceride-glucose (TyG) index, flag hidden insulin resistance more sensitively than weight alone, though the results need a clinician to interpret. One thing to be cautious about is the "visceral fat" reading on a consumer smart scale. These devices track whole-body fat trends reasonably, but their visceral-fat readings have been found unreliable against imaging in validation studies, so treat that figure as a rough trend rather than a diagnostic measure.

If your BMI is normal but your waist, family history or blood results suggest otherwise, that gap is exactly what a metabolic health check with a clinician is designed to address. A registered doctor can put your waist, blood results and history together and explain what they actually mean for you, which is something no single number and no article can do.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.